Media & Speaking
About
Aliza Olive, MD, and Kellie Bader, PharmD, are the co-founders of GLP1 Enhanced, a clinical nutrition and education platform designed to help patients and healthcare organizations optimize long-term outcomes with GLP-1 medications.
Dr. Olive is a board-certified pediatric intensivist and ethics researcher whose clinical work centers on complex medical decision making and long-term patient outcomes. Kellie is a pharmacist with extensive experience in nutrition coaching, medication management, and metabolic health education.
Together, they recognized a growing gap between prescribing GLP-1 medications and supporting sustainable results after weight loss begins. Through GLP1 Enhanced, they work with individuals, clinics, and telehealth organizations to address muscle preservation, metabolic adaptation, nutrition strategy, and successful medication tapering.
They are co-authors of GLP-1 Meals Made Easy and frequently speak on the future of obesity care, patient support beyond prescriptions, and sustainable approaches to metabolic health.
Podcast Topics
What nobody tells patients after starting GLP-1 medications
Why eating less is not the goal of successful weight loss
Preventing muscle loss and metabolic slowdown on GLP-1s
What happens when insurance coverage stops
How healthcare systems can better support sustainable weight loss
GLP1 Enhanced Meals Made Easy
As Seen On:
Are you currently or considering taking a GLP-1 drug to help you lose weight? These include the semaglutide (like Ozempic and Wegovy) and tirzepatide (like Mounjaro and Zepbound).
What happens if you want to wean off? This is precisely the question we set out to answer in this week’s episode. Of course not everyone that uses these medications has the desire to wean off. And that’s ok. But if you are thinking you’d like to try a weight loss medication, but are worried about the after effects, this episode is for you!
Even if weight loss medication isn’t your jam, this episode is all about weight loss truths, whether you are taking a medication or not.
Today I am joined by my friend Kellie Bader. Kellie is a pharmacist and a GLP-1 coach for women. She brings both clinical expertise and real life coaching experience to the conversation. We are diving into what GLP-1 medications are, who they are for, how they work, and what people need to understand before starting them. We also cover the lifestyle side of GLP-1 use including how to maintain progress and how to transition off safely and successfully.
Inside this episode:
What GLP-1 medications actually are
Who they were created for and who might benefit now
Common myths and misunderstandings
How lifestyle habits impact results
What to consider before starting or stopping
How coaching support can help maintain long-term success
In this episode, I talk with Aliza and Kellie, the powerhouse duo behind GLP-1 Enhanced, whose coaching has helped thousands navigate weight loss medication with confidence and clarity. We dive into how they met, how their own experiences with semaglutide and tirzepatide shaped their work, and why they believe slow, intentional weight loss is the key to protecting both muscle and mental health.
They share the real challenges they faced on medication — from protein aversion to side effects to the emotional shifts that happen when food noise suddenly disappears — and how those experiences inspired their approach to sustainable nutrition and support. We also explore the stigma around GLP-1s, the differences between healthcare in the U.S. and Sweden, and the misunderstandings that still shape how people talk about these medications.
Aliza and Kellie explain their philosophy behind Master Your Taper, their method for transitioning off medication through reverse dieting and mindful calorie increases — a process designed to help people keep their results without fear or rebound.
This is an open, encouraging conversation about what real, healthy weight loss looks like with GLP-1s — and why no one should have to figure it out alone.
Join MD Newsline’s panel, GLP-1s in the Real World: What the Data Is Telling Us So Far, for an important conversation on how these medications are shaping the future of obesity and metabolic care. This expert discussion looks beyond headlines to explore real-world outcomes, including effectiveness, adherence challenges, patient expectations, safety considerations, and long-term management.